InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Source: Newsfilter
- Significant Revenue Growth: InterCure reported over NIS 270 million in revenue for 2025, a 13% increase year-over-year, with NIS 140 million in the second half, reflecting a 24% growth compared to the same period in 2024, indicating strong market recovery.
- Consistent Positive Adjusted EBITDA: The company achieved an Adjusted EBITDA of NIS 47 million in 2025, over 90% higher than 2024, representing 17% of revenue, marking the twelfth consecutive half-year of positive Adjusted EBITDA, showcasing sustained profitability.
- Positive Operating Cash Flow: InterCure generated NIS 17 million in positive operating cash flow in 2025, a significant turnaround from a negative cash flow of NIS 67 million in 2024, demonstrating substantial progress in resuming production and sales.
- Strategic Acquisitions and Partnerships: The company entered into a strategic investment agreement with Cannasoul R&D Ltd., acquiring a 28% stake with plans to increase to 51% within two years, enhancing its research capabilities and supporting its positioning in the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCR
About INCR
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InterCure Reports Significant FY Revenue Growth
- Strong Financial Performance: InterCure's fiscal year revenue reached NIS 270.2 million, reflecting significant growth compared to the previous year, indicating the company's robust market performance and business expansion capabilities.
- Adjusted EBITDA Surge: The adjusted EBITDA of NIS 47 million represents a more than 90% increase from NIS 24 million in 2024, accounting for 17% of total revenue, showcasing the company's enhanced profitability.
- Reduced Net Loss: The company reported a net loss of NIS 37 million, a substantial decrease from NIS 73 million in 2024, primarily reflecting non-cash provisions related to Bazalet debt and the impact of the ongoing war.
- Nasdaq Notification: InterCure received a notification from Nasdaq regarding minimum bid requirements, indicating challenges faced in the capital markets, necessitating measures to ensure compliance and maintain investor confidence.
See More
InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA
- Significant Revenue Growth: InterCure reported over NIS 270 million in revenue for 2025, a 13% increase year-over-year, with NIS 140 million in the second half, reflecting a 24% growth compared to the same period in 2024, indicating strong market recovery.
- Consistent Positive Adjusted EBITDA: The company achieved an Adjusted EBITDA of NIS 47 million in 2025, over 90% higher than 2024, representing 17% of revenue, marking the twelfth consecutive half-year of positive Adjusted EBITDA, showcasing sustained profitability.
- Positive Operating Cash Flow: InterCure generated NIS 17 million in positive operating cash flow in 2025, a significant turnaround from a negative cash flow of NIS 67 million in 2024, demonstrating substantial progress in resuming production and sales.
- Strategic Acquisitions and Partnerships: The company entered into a strategic investment agreement with Cannasoul R&D Ltd., acquiring a 28% stake with plans to increase to 51% within two years, enhancing its research capabilities and supporting its positioning in the U.S. market.
See More
InterCure Receives Noncompliance Notice from Nasdaq
- Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
- Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
- Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
- Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.
See More
InterCure Receives Nasdaq Compliance Notice
- Compliance Notice: InterCure received a written notice from Nasdaq indicating non-compliance with listing rules due to its ordinary shares closing bid price being below $1.00 for the last 30 consecutive business days.
- Compliance Period: The company has been granted a 180-calendar-day compliance period until August 24, 2026, allowing it time to regain compliance with the minimum bid price requirement, which is crucial for maintaining its listing status.
- Subsequent Measures: If compliance is not achieved by the deadline, InterCure expects to be eligible for an additional 180-calendar-day compliance period, providing further opportunity to improve its stock price performance.
- Market Impact: This compliance notice may negatively affect investor confidence, particularly as the company faces stock price pressure, potentially impacting its ability to raise funds and its market image.
See More
Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase
Trump's Executive Order Impact: A leveraged ETF focused on the American cannabis industry is expected to rise following President Trump's executive order aimed at easing federal restrictions on cannabis.
AdvisorShares MSOS Daily Leveraged ETF: The AdvisorShares MSOS Daily Leveraged ETF has seen a significant increase in its Momentum score, indicating strong investor interest amid regulatory changes, despite a recent pullback in its value.
Market Volatility: The fund experienced a notable decline of 50.59% after a previous drop of 26.91%, attributed to uncertainties regarding banking regulations in Trump's order, which were anticipated by the industry.
Overall Market Sentiment: Despite a high Momentum score, the ETF faces unfavorable price trends in the short, medium, and long term, reflecting mixed market sentiment towards cannabis stocks.
See More
InterCure Joins High-End US Cannabis Market Through ISHI Agreement
InterCure's Acquisition of Botanico: InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI) to enhance its global cannabis portfolio, gaining access to advanced cultivation technologies and brand partnerships in the U.S. cannabis market.
Regulatory Context and Future Plans: The acquisition coincides with potential regulatory changes regarding cannabis scheduling in the U.S., and InterCure plans to complete the deal by Q1 2026, pending approvals, while integrating ISHI's leadership and assets.
See More
InterCure Reports Significant FY Revenue Growth
- Strong Financial Performance: InterCure's fiscal year revenue reached NIS 270.2 million, reflecting significant growth compared to the previous year, indicating the company's robust market performance and business expansion capabilities.
- Adjusted EBITDA Surge: The adjusted EBITDA of NIS 47 million represents a more than 90% increase from NIS 24 million in 2024, accounting for 17% of total revenue, showcasing the company's enhanced profitability.
- Reduced Net Loss: The company reported a net loss of NIS 37 million, a substantial decrease from NIS 73 million in 2024, primarily reflecting non-cash provisions related to Bazalet debt and the impact of the ongoing war.
- Nasdaq Notification: InterCure received a notification from Nasdaq regarding minimum bid requirements, indicating challenges faced in the capital markets, necessitating measures to ensure compliance and maintain investor confidence.
See More
InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA
- Significant Revenue Growth: InterCure reported over NIS 270 million in revenue for 2025, a 13% increase year-over-year, with NIS 140 million in the second half, reflecting a 24% growth compared to the same period in 2024, indicating strong market recovery.
- Consistent Positive Adjusted EBITDA: The company achieved an Adjusted EBITDA of NIS 47 million in 2025, over 90% higher than 2024, representing 17% of revenue, marking the twelfth consecutive half-year of positive Adjusted EBITDA, showcasing sustained profitability.
- Positive Operating Cash Flow: InterCure generated NIS 17 million in positive operating cash flow in 2025, a significant turnaround from a negative cash flow of NIS 67 million in 2024, demonstrating substantial progress in resuming production and sales.
- Strategic Acquisitions and Partnerships: The company entered into a strategic investment agreement with Cannasoul R&D Ltd., acquiring a 28% stake with plans to increase to 51% within two years, enhancing its research capabilities and supporting its positioning in the U.S. market.
See More
InterCure Receives Noncompliance Notice from Nasdaq
- Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
- Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
- Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
- Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.
See More
InterCure Receives Nasdaq Compliance Notice
- Compliance Notice: InterCure received a written notice from Nasdaq indicating non-compliance with listing rules due to its ordinary shares closing bid price being below $1.00 for the last 30 consecutive business days.
- Compliance Period: The company has been granted a 180-calendar-day compliance period until August 24, 2026, allowing it time to regain compliance with the minimum bid price requirement, which is crucial for maintaining its listing status.
- Subsequent Measures: If compliance is not achieved by the deadline, InterCure expects to be eligible for an additional 180-calendar-day compliance period, providing further opportunity to improve its stock price performance.
- Market Impact: This compliance notice may negatively affect investor confidence, particularly as the company faces stock price pressure, potentially impacting its ability to raise funds and its market image.
See More
Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase
Trump's Executive Order Impact: A leveraged ETF focused on the American cannabis industry is expected to rise following President Trump's executive order aimed at easing federal restrictions on cannabis.
AdvisorShares MSOS Daily Leveraged ETF: The AdvisorShares MSOS Daily Leveraged ETF has seen a significant increase in its Momentum score, indicating strong investor interest amid regulatory changes, despite a recent pullback in its value.
Market Volatility: The fund experienced a notable decline of 50.59% after a previous drop of 26.91%, attributed to uncertainties regarding banking regulations in Trump's order, which were anticipated by the industry.
Overall Market Sentiment: Despite a high Momentum score, the ETF faces unfavorable price trends in the short, medium, and long term, reflecting mixed market sentiment towards cannabis stocks.
See More
InterCure Joins High-End US Cannabis Market Through ISHI Agreement
InterCure's Acquisition of Botanico: InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI) to enhance its global cannabis portfolio, gaining access to advanced cultivation technologies and brand partnerships in the U.S. cannabis market.
Regulatory Context and Future Plans: The acquisition coincides with potential regulatory changes regarding cannabis scheduling in the U.S., and InterCure plans to complete the deal by Q1 2026, pending approvals, while integrating ISHI's leadership and assets.
See More
